Screener
ClearPoint Neuro CLPT CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Contract liabilities | 172 | (581) |
| Net cash flows from operating activities | (7,967) | (6,172) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (645) | (183) |
| Net cash flows from investing activities | (645) | (183) |
| Cash flows from financing activities: | ||
| Payment of At-The-Market offering costs | — | (78) |
| Proceeds from stock option exercises | 148 | 21 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's capex?
- ClearPoint Neuro (CLPT) reported capex of $645K in Q1 2026.
- How has ClearPoint Neuro's capex changed year-over-year?
- ClearPoint Neuro's capex increased by 252.5% year-over-year, from $183K to $645K.
- What is the long-term trend for ClearPoint Neuro's capex?
- Over 3 years (2022 to 2025), ClearPoint Neuro's capex has grown at a 27.3% compound annual growth rate (CAGR), from $253K to $522K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about ClearPoint Neuro's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude